Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer
Thorsten Oost(Abbott (United States)), Stephen W. Fesik(Vanderbilt University), Tilman Oltersdorf(Harvard University), Stephen F. Betz(Abbott (United States)), Robert Meadows(Abbott (United States)), Andrew Oleksijew(Abbott (United States)), Hong Ding(Abbott (United States)), Robert C. Armstrong, Steven W. Elmore(AbbVie (United States)), Thomas L. Deckwerth, Kevin J. Tomaselli, Alexander R. Shoemaker(Abbott Fund), Hua Zou(Children's Hospital of Chongqing Medical University), Saul H. Rosenberg(Abbott Fund), Chaohong Sun(AbbVie (United States)), Edward T. Olejniczak(Abbott (United States)), Ali-Samer Al-Assaad(Abbott (United States))
Cited by 364
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k